日本东京及大阪新冠疫苗大规模接种中心启用
《共同社》报道,日本自卫队以首都圈1都3县和关西3府县老年人为对象运营的新冠疫苗大规模接种中心,今日(24日)上午在东京与大阪开设并启动了接种工作,至30日将给东京23区和大阪市居民接种,而使用的是厚生劳动省於21日批准的美国莫德纳(MRNA.US)生产疫苗。
日本中央政府提出的目标是到7月底前完成老年人接种,作为防疫的王牌,决定设置动用自卫队的大规模设施。预计东京和大阪的中心最多每日分别接种1万人和5,000人。
另外,各地方政府也陆续制定了设置大规模接种会场的计划,宫城、群马和爱知各县於24日启用。中央政府也将提供支援,力争增加接种人数。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.